# Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

> **NCT02874846** · PHASE2 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Ocular Hypertension
- Open Angle Glaucoma

## Interventions

- **DRUG:** Netarsudil ophthalmic solution 0.02%
- **OTHER:** Netarsudil Ophthalmic Solution Vehicle

## Key facts

- **NCT ID:** NCT02874846
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2018-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02874846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02874846, "Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02874846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*